company background image
SCS

Stem Cells Spin WSE:SCS Stock Report

Last Price

zł0.35

Market Cap

zł14.6m

7D

-4.9%

1Y

-67.1%

Updated

25 May, 2022

Data

Company Financials
SCS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SCS Stock Overview

Stem Cells Spin S.A., a biotechnology company, focuses on the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets; and applications for the human and veterinary medical industry primarily in Poland.

Stem Cells Spin Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Stem Cells Spin
Historical stock prices
Current Share Pricezł0.35
52 Week Highzł1.36
52 Week Lowzł0.32
Beta1.06
1 Month Change-12.00%
3 Month Change-15.38%
1 Year Change-67.10%
3 Year Change-20.00%
5 Year Change-51.78%
Change since IPO-84.36%

Recent News & Updates

Shareholder Returns

SCSPL BiotechsPL Market
7D-4.9%-1.7%6.3%
1Y-67.1%-39.0%-42.2%

Return vs Industry: SCS underperformed the Polish Biotechs industry which returned -38.8% over the past year.

Return vs Market: SCS underperformed the Polish Market which returned -15% over the past year.

Price Volatility

Is SCS's price volatile compared to industry and market?
SCS volatility
SCS Average Weekly Movement14.7%
Biotechs Industry Average Movement7.1%
Market Average Movement6.8%
10% most volatile stocks in PL Market13.4%
10% least volatile stocks in PL Market4.5%

Stable Share Price: SCS is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: SCS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
20092Andrzej Kryzarhttps://stemcellsspin.com.pl

Stem Cells Spin S.A., a biotechnology company, focuses on the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets; and applications for the human and veterinary medical industry primarily in Poland. The company’s products comprise NHAC Biocervin MIC-1, a therapy component that stimulates the skin to regenerate and reach the eyelash and eyebrow roots stopping their loss and initiating new hair growth; and protein-rich solution MIC-1, a natural cosmetic ingredient. It also provides Revitacell biodermocosmetcs skincare products, including face therapy, hair therapy, eyelashes therapy, regenerating cream-serum day, regenerating and nourishing cream-serum night, eye zone regenerating concentrate, regenerating face balm for men, bust set, hand set, and face set products, as well as regenerating and anti-aging MIC-1 mesotherapy; and veterinary care products consisting of regenerating care balms, antibacterial regenerating ointments, and regenerating and warming rub ointments under the Velvetyna brand name.

Stem Cells Spin Fundamentals Summary

How do Stem Cells Spin's earnings and revenue compare to its market cap?
SCS fundamental statistics
Market Capzł14.55m
Earnings (TTM)-zł131.14k
Revenue (TTM)zł305.27k

47.7x

P/S Ratio

-111.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SCS income statement (TTM)
Revenuezł305.27k
Cost of Revenuezł22.48k
Gross Profitzł282.79k
Other Expenseszł413.92k
Earnings-zł131.14k

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 16, 2022

Earnings per share (EPS)-0.0032
Gross Margin92.64%
Net Profit Margin-42.96%
Debt/Equity Ratio6.4%

How did SCS perform over the long term?

See historical performance and comparison

Valuation

Is Stem Cells Spin undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: SCS (PLN0.35) is trading below our estimate of fair value (PLN0.87)

Significantly Below Fair Value: SCS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SCS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Polish Biotechs industry average.

PE vs Market: SCS is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SCS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SCS is good value based on its Price-To-Book Ratio (1.9x) compared to the PL Biotechs industry average (3.7x).


Future Growth

How is Stem Cells Spin forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stem Cells Spin has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Stem Cells Spin performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-2.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SCS is currently unprofitable.

Growing Profit Margin: SCS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SCS is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare SCS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: SCS has a negative Return on Equity (-1.7%), as it is currently unprofitable.


Financial Health

How is Stem Cells Spin's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SCS's short term assets (PLN752.5K) exceed its short term liabilities (PLN228.6K).

Long Term Liabilities: SCS's short term assets (PLN752.5K) do not cover its long term liabilities (PLN7.6M).


Debt to Equity History and Analysis

Debt Level: SCS's net debt to equity ratio (5.3%) is considered satisfactory.

Reducing Debt: SCS's debt to equity ratio has reduced from 127.3% to 6.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SCS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SCS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 72.3% per year.


Dividend

What is Stem Cells Spin current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SCS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SCS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SCS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SCS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Andrzej Kryzar

no data

Tenure

Andrzej Kryzar is President of the Management Board of Stem Cells Spin S.A.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Stem Cells Spin S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Stem Cells Spin S.A.
  • Ticker: SCS
  • Exchange: WSE
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł14.550m
  • Shares outstanding: 41.34m
  • Website: https://stemcellsspin.com.pl

Number of Employees


Location

  • Stem Cells Spin S.A.
  • ul. Konopnickiej 15 b
  • Wroclaw
  • 51-141
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.